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Fludarabine induced Immune Thrombocytopenia in a patient with CD5 Positive B
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Department Of Pathology, The Aga Khan University Hospital, Karachi.
Introduction
Fludarabine is a purine nucleoside analogue, which inhibits
DNA synthesis by inhibiting DNA polymerase and ribonucleoside
reductase.1 It affects both dividing and non- dividing cells.2
Fludarabine possesses proven efficacy in the treatment of a variety of
indolent B cell lymphoproliferative disorders including chronic lym-
phocytic leukemia3, low-grade non-Hodgkin's lymphoma4 and
Waldenstrom macroglobulinemia.5 It is also a part of conditioning
regimes in non-myeloablative bone marrow transplantation.6 The
common side effects include myelosuppression, immunosuppression,
and neurologic toxicity.7 The rare side effects are immune mediated
hemolytic anemia8 and thrombocytopenia.9 Here we describe a case of
a middle-aged lady who was diagnosed as B cell chronic lymphocyt-
ic leukemia and developed immune mediated thrombocytopenia fol-
lowing oral Fludarabine.
Case Report
Fifty years old female presented to the hematology outpatient
with a history of low-grade fever, weight loss and painless swellings
on both sides of neck since one month. She was a known patient of
diabetes mellitus and hypertension. There was no previous history of
autoimmune diseases. Examination at the time of presentation
revealed bilateral cervical and axillary lymphadenopathy. Spleen was
palpable 3cm below the left subcostal margin. Rest of the general and
systemic examination was unremarkable. Investigations revealed
hemoglobin 12.1 gm/dl, white cells count 35,500/cumm and platelets
277,000/cumm. Absolute lymphocyte count was 28,000/cumm. Bone
marrow and bone trephine findings were consistent with the diagnosis
of lymphoproliferative disorder (chronic lymphocytic leukemia).
Immuno-phenotyping revealed positivity against CD5, CD19, CD20
and CD22 and hence consistent with B cell chronic lymphocytic
leukemia. Other laboratory investigations were within normal ranges.
Serial blood counts subsequently revealed progressive increase in
absolute lymphocyte count along with an increase in the percentage of
prolymphocytes. On physical examination, there was an increase in
the number and size of lymph nodes of cervical region.  
Initially she received three cycles of tablet chlorambucil 10mg
PO daily for two weeks in a cycle of four weeks with no improvement.
She was started on tablet Fludarabine 25mg per meter square for five
days every four weeks. She responded well to the treatment. After
four cycles of Fludarabine, she developed petechial hemorrhages on
both legs, spontaneous epistaxis, bleeding from left ear and malena.
She was admitted in the hospital and the complete blood count
showed hemoglobin 7.9 gm/dl, white cell count 6100/cumm and
platelet count 3000/cumm. Bone marrow aspiration and trephine was
done. It was a cellular specimen showing normal maturation of ery-
erythroid and myeloid precursors along with plentiful
megakaryocytes suggesting immune mediated destruction of
platelets. There was clearance of the disease.  She was started on
Prednisolone 30mg PO bid, but the symptoms persisted with the
platelet counts remaining less than 10,000/cumm. She received a
course of intravenous immunoglobulin 1gm/kg for two days. Her
symptoms improved and the platelet counts gradually increased.
Platelets counts stabilized to more than 150,000/cumm in six
weeks time. 
Discussion
Patients with lymphoproliferative disorders have an
increased risk of autoimmune disorders such as autoimmune
hemolytic anemia and thrombocytopenia.10,11 Pathogenesis is
obscure, however it has been postulated that leukemic B cells
elaborate immune suppressive cytokines, such as transforming
growth factor beta, which may account for the reversal in the ratio
of CD4 to CD8 T cells.12 There is also a down regulatory expres-
sion of CD154 (CD40-ligand), a surface glycoprotien that is
expressed on CD4 + T cells following immune activation.
Because CD154 (CD40-ligand) plays a critical role in the devel-
opment of an immune response, such down modulation may be
responsible for an immune deficiency state.13,14 Fludarabine is a
potent suppressor of T lymphocytes and this drug may accelerate
the pre existing T cell immune suppression that normally occur
during progression of chronic lymphocytic leukemia, exacerbat-
ing the underlying tendency to autoimmunity.11 The pathogenic
autoantibodies generally do not appear to be produced by the
malignant B cell clone.15
This patient developed immune mediated thrombocytope-
nia after four courses of Fludarabine and recovered completely in
six weeks time. As it has been observed that these patients usual-
ly recover within ten weeks9 so the option of splenectomy should
be reserved for those patients who are refractory to first line ther-
apy with persistent significant thrombocytopenia for more than
ten weeks. Re-exposure to the drug can lead to recurrent thrombo-
cytopenia9, so it is advisable not to rechallenge the patient who
has had an episode of immune mediated thrombocytopenia.
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